Abhinav Deol, MD

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.

Abhinav Deol, MD, discusses the sequencing of CAR T-cell therapies with other readily available agents in multiple myeloma.

Abhinav Deol, MD, discusses the selection of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.

Abhinav Deol, MD, discusses the efficacy and durability of CAR T-cell therapies in patients with multiple myeloma.

Abhinav Deol, MD, discusses the current limitations of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

Abhinav Deol, MD, discusses the importance of communication and collaboration in CAR T-cell therapy.

Abhinav Deol, MD, discusses shifting CAR T-cell therapy to earlier lines of therapy in cancer care.

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

Abhinav Deol, MD, discusses the approval of the CAR T-cell therapy tisagenlecleucel for pediatric patients with acute lymphoblastic leukemia.

Abhinav Deol, MD, discusses the nuances of utilizing CAR T-cell therapy in lymphoma and leukemia.

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.